Remote biometric sensing (RBS) use after hospital discharge was associated with a lower 30-day mortality risk (RR 0.63; 95% CI 0.46-0.85).
Meta-Analysis
Does the use of remote biometric sensing devices reduce all-cause readmission and mortality rates in adult patients discharged from the hospital?
The use of remote biometric sensing devices after hospital discharge is associated with a reduced 30-day mortality risk.
Effect estimate: RR 0.63 (95% CI 0.46-0.85)
INTRODUCTION: Unplanned hospital readmissions are associated with higher morbidity, mortality, and financial burden. This study evaluated the association between the use of remote biometric sensing devices (RBS) and all-cause readmission and mortality rates among adult patients discharged from the hospital. METHODS: We systematically searched MEDLINE, Embase, Scopus, and Global Health from inception to August 2023. Eligible studies assessed adult patients using RBS devices, defined as tools capable of automatically or manually measuring at least one biometric marker beyond physical activity, after hospital discharge. Studies required a comparison group and reported all-cause readmission rates. Risk ratios (RRs) with 95% confidence intervals (CIs) were summarized using random-effects models to account for variability. Subgroup analysis was conducted based on study design, follow-up period postdischarge, and index discharge diagnosis. RESULTS: = 0%). RBS use was associated with lower 30-day mortality risk (RR = 0.63; 95% CI: 0.46-0.85), with no significant associations thereafter. CONCLUSION: Among patients recently discharged from the hospital, RBS use is associated with improved short-term outcomes. Future studies are needed to validate these findings.
Farahani et al. (Tue,) conducted a meta-analysis in Recently discharged adult patients. Remote biometric sensing devices (RBS) vs. Comparison group was evaluated on 30-day mortality risk (RR 0.63, 95% CI 0.46-0.85). Remote biometric sensing (RBS) use after hospital discharge was associated with a lower 30-day mortality risk (RR 0.63; 95% CI 0.46-0.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: